A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year

References

• Daniels K, Daugherty J, Jones J, et al. Current contraceptive use and variation by selected characteristics among women aged 15–44: united states, 2011–2013. Hyattsville, MD:National Center for Health Statistics; 2015. Available from: https://www.cdc.gov/nchs/data/nhsr/nhsr086.pdf
   Google Scholar
• Kavanaugh ML, Jerman J. Contraceptive method use in the united states: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14–21.
   PubMed Web of Science ®Google Scholar
• Sonfield A, Hasstedt K, Gold RB. Moving forward: family planning in the era of health reform. New York, NY:Guttmacher Institute; 2014. Available from: https://www.guttmacher.org/report/moving-forward-family-planning-era-health-reform
   Google Scholar
• Finer LB, Zolna MR. Declines in unintended pregnancy in the united states, 2008-2011. N Engl J Med. 2016;374(9):843–852.
   PubMed Web of Science ®Google Scholar
• Daniels K, Mosher W, Jones J. Contraceptive methods women have ever used: United States, 1982–2010. Hyattsville, MD: National Center for Health Statistics; 2013.
   Google Scholar
• Trussell J. Contraceptive failure in the united states. Contraception. 2011;83(5):397–404.
   PubMed Web of Science ®Google Scholar
• Annovera: segesterone acetate and ethinyl estradiol vaginal system [package insert]. U.S. Food and Drug Administration, (2018) [cited 2019 Dec 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209627Orig1s000TOC.cfm
   Google Scholar
• Mishell DR Jr., Lumkin ME. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. Fertil Steril. 1970;21(2):99–103.
   PubMed Web of Science ®Google Scholar
• Mishell DR Jr., Talas M, Parlow AF, et al. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol. 1970;107(1):100–107.
   PubMed Web of Science ®Google Scholar
• Nuvaring: etonogestrel/ethinyl estradiol vaginal ring [package insert]. U.S. Food and Drug Administration, (2005). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021187s012lbl.pdf
   Google Scholar
• Algorta J, Diaz M, de Benito R, et al. Pharmacokinetic bioequivalence, safety and acceptability of ornibel((r)), a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with nuvaring((r)) (etonogestrel/ethinylestradiol 11.7/2.7 mg). Eur J Contracept Reprod Health Care. 2017;22(6):429–438.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–66.
   Web of Science ®Google Scholar
• Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103.
   Web of Science ®Google Scholar
• Archer DF, Merkatz RB, Bahamondes L, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health. 2019;7(8):e1054–e1064.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Kuhl H. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care. 2006;11(3):153–161.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994;170(5 Pt 2):1499–1507.
   PubMed Web of Science ®Google Scholar
• RamaRao S, Clark H, Merkatz R, et al. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception. 2013;88(5):591–598.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Vaginal delivery of contraceptives. Expert Opin Drug Deliv. 2005;2(4):729–736.
   PubMedGoogle Scholar
• Alexander NJ, Baker E, Kaptein M, et al. Why consider vaginal drug administration? Fertil Steril. 2004;82(1):1–12.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003552.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception. 2010;82(5):410–417.
   PubMed Web of Science ®Google Scholar
• Edelman A, Sitruk-Ware R, Kumar N, et al. A novel contraceptive vaginal ring releasing nestorone and estradiol dosed continuously: pharmacokinetics from a dose finding study. Fertil Steril. 2017;108(3):e121.
   Web of Science ®Google Scholar
• Brache V, Mishell DR, Lahteenmaki P, et al. Ovarian function during use of vaginal rings delivering three different doses of nestorone. Contraception. 2001;63(5):257–261.
   PubMed Web of Science ®Google Scholar
• Sivin I, Croxatto H, Bahamondes L, et al. Two-year performance of a nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception. 2004;69(2):137–144.
   PubMed Web of Science ®Google Scholar
• Brache V, Massai R, Mishell DR, et al. Ovarian function during use of nestorone(r) subdermal implants. Contraception. 2000;61(3):199–204.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Kumar N, et al. An initial pharmacokinetic study with a metered dose transdermal systemfor delivery of the progestogen nestorone as a possible future contraceptive. Contraception. 2007;76(6):432–438.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Small M, Kumar N, et al. Nestorone: clinical applications for contraception and hrt. Steroids. 2003;68(10–13):907–913.
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000;65(10–11):629–636.
   PubMed Web of Science ®Google Scholar
• Lahteenmaki P, Weiner E, Lahteenmaki P, et al. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, st-1435. Contraception. 1982;25(3):299–306.
   PubMed Web of Science ®Google Scholar
• Haukkamaa M, Laurikka-Routti M, Heikinheimo O, et al. Contraception with subdermal implants releasing the progestin st-1435: a dose-finding study. Contraception. 1992;45(1):49–55.
   PubMed Web of Science ®Google Scholar
• Lahteenmaki PL, Kurunmaki H, Lahteenmaki P, et al. Pharmacokinetic observations on st-1435 administered subcutaneously and intravaginally. Contraception. 1984;30(4):381–389.
   PubMed Web of Science ®Google Scholar
• Laurikka-Routti M, Haukkamaa M. A contraceptive subdermal implant releasing the progestin st-1435: ovarian function, bleeding patterns, and side effects. Fertil Steril. 1992;58(6):1142–1147.
   PubMed Web of Science ®Google Scholar
• Creasy G, Brache V, Croxatto H. User controlled long acting reversible contraception: the pharmacokinetic profile of the nesterone/ethinyl estradiol contraceptive vaginal ring (nes/ee-cvr) a 1-year cyclical re-useable vaginal ring. Eur J Contracept Reprod Health Care. 2014;19(S85).
   Google Scholar
• Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin st-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception. 1990;42(1):111–120.
   PubMed Web of Science ®Google Scholar
• Alvarez-Sanchez F, Brache V, Jackanicz T, et al. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception. 1992;46(4):387–398.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Brache V, et al. Serum nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception. 2005;72(1):40–45.
   PubMed Web of Science ®Google Scholar
• Sivin I, Mishell DR Jr., Alvarez F, et al. Contraceptive vaginal rings releasing nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception. 2005;71(2):122–129.
   PubMed Web of Science ®Google Scholar
• Vieira CS, Fraser IS, Plagianos MG, et al. Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from phase 3 trials. Contraception. 2019 Dec;100(6):438–444.
   Web of Science ®Google Scholar
• Belsey EM, Machin D, d’Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World health organization special programme of research, development and research training in human reproduction. Contraception. 1986;34(3):253–260.
   PubMedGoogle Scholar
• Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD, et al. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019 Jun;99(6):323–328.
   Web of Science ®Google Scholar
• Roumen FJ, Mishell DR Jr. The contraceptive vaginal ring, nuvaring((r)), a decade after its introduction. Eur J Contracept Reprod Health Care. 2012;17(6):415–427.
   PubMed Web of Science ®Google Scholar
• Huang Y, Merkatz RB, Hillier SL, et al. Effects of a one year reusable contraceptive vaginal ring on vaginal microflora and the risk of vaginal infection: an open-label prospective evaluation. PLoS One. 2015;10(8):e0134460.
   PubMed Web of Science ®Google Scholar
• Linhares IM, Giraldo PC, Baracat EC. [new findings about vaginal bacterial flora]. Rev Assoc Med Bras (1992). 2010;56(3):370–374.
   PubMedGoogle Scholar
• Crucitti T, Hardy L, van de Wijgert J, et al. Ring Plus study g: contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: a randomised, open-label longitudinal study in rwandan women. PLoS One. 2018;13(7):e0201003.
   PubMed Web of Science ®Google Scholar
• Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004;104(3):555–563.
   PubMed Web of Science ®Google Scholar
• Simmons KB, Kumar N, Plagianos M, et al. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of nestorone(r) (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Contraception. 2018;97(3):270–276.
   PubMed Web of Science ®Google Scholar
• Archer DF, Thomas MA, Conard J, et al. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering nestorone(r) and ethinyl estradiol. Contraception. 2016;93(1):58–64.
   PubMed Web of Science ®Google Scholar
• Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014;171(6):R221–230.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Jensen J. Chapter 2. Reproduction and hormonal contraception. In: Jensen JT, Creinin MD, Speroff L, editors. Speroff & darney’s clinical guide to contraception. Philadelphia: Wolters Kluwer; 2020. p. 31–66.
   Google Scholar
• Dinger J, Mohner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013;122(4):800–808.
   PubMed Web of Science ®Google Scholar
• Merkatz RB, Plagianos M, Hoskin E, et al. Acceptability of the nestorone(r)/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction. Contraception. 2014;90(5):514–521.
   PubMed Web of Science ®Google Scholar
• Hatcher RA, Nelson AL, Trussell J, et al. Contraceptive technology. Atlanta: Managing Contraception LLC; 2018.
   Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the esther study. Circulation. 2007;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Tremollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28(5):400–408.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Edelman AB, Chen BA, et al. Continuous dosing of a novel contraceptive vaginal ring releasing nestorone(r) and estradiol: pharmacokinetics from a dose-finding study. Contraception. 2018;97(5):422–427.
   PubMed Web of Science ®Google Scholar
• Duijkers I, Klipping C, Heger-Mahn D, et al. Phase ii dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17beta-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to nuvaring. Eur J Contracept Reprod Health Care. 2018;23(4):245–254.
   PubMed Web of Science ®Google Scholar
• Benson LS, Micks EA. Why stop now? Extended and continuous regimens of combined hormonal contraceptive methods. Obstet Gynecol Clin North Am. 2015;42(4):669–681.
   PubMed Web of Science ®Google Scholar
• Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. Cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014 Jul 29;(7):CD004695.
   Web of Science ®Google Scholar
• Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41–47.
   PubMedGoogle Scholar
• Bearak JM, Jones RK. Did contraceptive use patterns change after the affordable care act? A descriptive analysis. Womens Health Issues. 2017;27(3):316–321.
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Brache V, Massai R, et al. Feasibility study of nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception. Contraception. 2006;73(1):46–52.
   PubMed Web of Science ®Google Scholar
• Amico JR, Bennett AH, Karasz A, et al. “She just told me to leave it”: women’s experiences discussing early elective iud removal. Contraception. 2016;94(4):357–361.
   PubMed Web of Science ®Google Scholar